Perspective Therapeutics’ (CATX) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Perspective Therapeutics (NYSE:CATX – Free Report) in a research report released on Monday morning, Benzinga reports. A number of other analysts have also recently commented on CATX. Bank of America initiated coverage on Perspective Therapeutics in a research report on Thursday, July 25th. They set a […]

Leave a Reply

Your email address will not be published.

Previous post BRP (NASDAQ:DOOO) Price Target Cut to $75.00 by Analysts at Citigroup
Next post Phreesia (NYSE:PHR) Price Target Raised to $28.00